Dr. Swarz co-founded and is CEO of the Israeli biotech firm ATED Therapeutics. He is also a Partner and Managing Director at M.M. Dillon & Company. Dr. Swarz had served as a Senior Managing Director at Caris & Company. Dr. Swarz brings 35 years of experience in product development and marketing, equity analysis, capital raising, and investment analysis for companies in various segments of the healthcare industry. Prior to joining Caris, Dr. Swarz was a Managing Director at FBR and Life Sciences Group where he was responsible for corporate finance, mergers and acquisitions and private financing. Before that, he was a partner at EGS Healthcare Capital Partners, a healthcare private equity fund investing in biotechnology, specialty pharmaceuticals, and medical device companies. As an equity analyst in biotechnology research at Credit Suisse First Boston and Goldman Sachs, Dr. Swarz was rated among Wall Street’s top ten analysts in biotechnology by Institutional Investor Magazine for ten years. Dr. Swarz was a National Institutes of Health Research Fellow in Neurovirology, completed a Postdoctoral Fellowship (Neurovirology) at Johns Hopkins School of Medicine’s Department of Neurology and earned a Ph.D. in Neuroscience from the University of Rochester, and a B.Sc. degree in Biological Sciences (with honors) from the University of California at Irvine.
